全文获取类型
收费全文 | 17744篇 |
免费 | 1406篇 |
国内免费 | 1574篇 |
出版年
2024年 | 28篇 |
2023年 | 193篇 |
2022年 | 531篇 |
2021年 | 996篇 |
2020年 | 656篇 |
2019年 | 795篇 |
2018年 | 759篇 |
2017年 | 522篇 |
2016年 | 747篇 |
2015年 | 1113篇 |
2014年 | 1332篇 |
2013年 | 1384篇 |
2012年 | 1661篇 |
2011年 | 1471篇 |
2010年 | 898篇 |
2009年 | 817篇 |
2008年 | 902篇 |
2007年 | 798篇 |
2006年 | 721篇 |
2005年 | 671篇 |
2004年 | 518篇 |
2003年 | 473篇 |
2002年 | 369篇 |
2001年 | 298篇 |
2000年 | 279篇 |
1999年 | 272篇 |
1998年 | 170篇 |
1997年 | 158篇 |
1996年 | 181篇 |
1995年 | 136篇 |
1994年 | 154篇 |
1993年 | 98篇 |
1992年 | 113篇 |
1991年 | 108篇 |
1990年 | 79篇 |
1989年 | 72篇 |
1988年 | 50篇 |
1987年 | 55篇 |
1986年 | 38篇 |
1985年 | 28篇 |
1984年 | 37篇 |
1983年 | 18篇 |
1982年 | 14篇 |
1981年 | 9篇 |
1979年 | 2篇 |
排序方式: 共有10000条查询结果,搜索用时 781 毫秒
201.
Rui Zhou Huiying Sun Siting Zheng Jingwen Zhang Dongqiang Zeng Jianhua Wu Zhenhua Huang Xiaoxiang Rong Jianping Bin Yulin Liao Min Shi Wangjun Liao 《Journal of cellular and molecular medicine》2020,24(5):3229-3241
The heterogeneity in prognoses and chemotherapeutic responses of colon cancer patients with similar clinical features emphasized the necessity for new biomarkers that help to improve the survival prediction and tailor therapies more rationally and precisely. In the present study, we established a s troma-related l ncRNA s ignature (SLS) based on 52 lncRNAs to comprehensively predict clinical outcome. The SLS model could not only distinguish patients with different recurrence and mortality risks through univariate analysis, but also served as an independent factor for relapse-free and overall survival. Compared with the conventionally used TNM stage system, the SLS model clearly possessed higher predictive accuracy. Moreover, the SLS model also effectively screened chemotherapy-responsive patients, as only patients in the low-SLS group could benefit from adjuvant chemotherapy. The following cell infiltration and competing endogenous RNA (ceRNA) network functional analyses further confirmed the association between the SLS model and stromal activation-related biological processes. Additionally, this study also identified three phenotypically distinct colon cancer subtypes that varied in clinical outcome and chemotherapy benefits. In conclusion, our SLS model may be a significant determinant of survival and chemotherapeutic decision-making in colon cancer and may have a strong clinical transformation value. 相似文献
202.
Yi‐zheng Wei Guo‐fu Zhu Chang‐qing Zheng Jing‐jie Li Shuo Sheng Dai‐di Li Guo‐qing Wang Feng Zhang 《Journal of cellular and molecular medicine》2020,24(16):9446-9456
Parkinson's disease (PD) is the second most prevalent central nervous system (CNS) degenerative disease. Oxidative stress is one of key contributors to PD. Nuclear factor erythroid‐2‐related factor 2 (Nrf2) is considered to be a master regulator of many genes involved in anti‐oxidant stress to attenuate cell death. Therefore, activation of Nrf2 signalling provides an effective avenue to treat PD. Ellagic acid (EA), a natural polyphenolic contained in fruits and nuts, possesses amounts of pharmacological activities, such as anti‐oxidant stress and anti‐inflammation. Recent studies have confirmed EA could be used as a neuroprotective agent in neurodegenerative diseases. Here, mice subcutaneous injection of rotenone (ROT)‐induced DA neuronal damage was performed to investigate EA‐mediated neuroprotection. In addition, adult Nrf2 knockout mice and different cell cultures including MN9D‐enciched, MN9D‐BV‐2 and MN9D‐C6 cell co‐cultures were applied to explore the underlying mechanisms. Results demonstrated EA conferred neuroprotection against ROT‐induced DA neurotoxicity. Activation of Nrf2 signalling was involved in EA‐mediated DA neuroprotection, as evidenced by the following observations. First, EA activated Nrf2 signalling in ROT‐induced DA neuronal damage. Second, EA generated neuroprotection with the presence of astroglia and silence of Nrf2 in astroglia abolished EA‐mediated neuroprotection. Third, EA failed to produce DA neuroprotection in Nrf2 knockout mice. In conclusion, this study identified EA protected against DA neuronal loss via an Nrf2‐dependent manner. 相似文献
203.
204.
FGFRL1 affects chemoresistance of small‐cell lung cancer by modulating the PI3K/Akt pathway via ENO1
Rui Chen Deyu Li Meng Zheng Bin Chen Ting Wei Yu Wang Man Li Weimei Huang Qin Tong Qi Wang Yaru Zhu Wei Fang Linlang Guo Shun Fang 《Journal of cellular and molecular medicine》2020,24(3):2123-2134
Fibroblast growth factor receptor‐like 1 (FGFRL1), a member of the FGFR family, has been demonstrated to play important roles in various cancers. However, the role of FGFRL1 in small‐cell lung cancer (SCLC) remains unclear. Our study aimed to investigate the role of FGFRL1 in chemoresistance of SCLC and elucidate the possible molecular mechanism. We found that FGFRL1 levels are significantly up‐regulated in multidrug‐resistant SCLC cells (H69AR and H446DDP) compared with the sensitive parental cells (H69 and H446). In addition, clinical samples showed that FGFRL1 was overexpressed in SCLC tissues, and high FGFRL1 expression was associated with the clinical stage, chemotherapy response and survival time of SCLC patients. Knockdown of FGFRL1 in chemoresistant SCLC cells increased chemosensitivity by increasing cell apoptosis and cell cycle arrest, whereas overexpression of FGFRL1 in chemosensitive SCLC cells produced the opposite results. Mechanistic investigations showed that FGFRL1 interacts with ENO1, and FGFRL1 was found to regulate the expression of ENO1 and its downstream signalling pathway (the PI3K/Akt pathway) in SCLC cells. In brief, our study demonstrated that FGFRL1 modulates chemoresistance of SCLC by regulating the ENO1‐PI3K/Akt pathway. FGFRL1 may be a predictor and a potential therapeutic target for chemoresistance in SCLC. 相似文献
205.
206.
Jialing Rong Xianqun Xu Yang Xiang Guohua Yang Xinliang Ming Siying He Bin Liang Xiaokang Zhang Fang Zheng 《Journal of cellular and molecular medicine》2020,24(6):3560-3571
Numerous studies have demonstrated that thioredoxin-interacting protein (TXNIP) expression of peripheral blood leucocytes is increased in coronary artery disease (CAD). However, the molecular mechanism of this phenomenon remained unclear. DNA methylation plays important roles in the regulation of gene expression. Therefore, we speculated there might be a close association between the expression of TXNIP and methylation. In this study, we found that compared with controls, DNA methylation at cg19693031 was decreased in CAD, while mRNA expressions of TXNIP and inflammatory factors, NLRP3, IL-1β, IL-18, were increased. Methylation at cg19693031 was negatively associated with TXNIP expression in the cohort, THP-1 and macrophages/foam cells. Furthermore, Transwell assay and co-cultured adhesion assay were performed to investigate functions of TXNIP on the migration of THP-1 or the adhesion of THP-1 on the surface of endothelial cells, respectively. Notably, overexpressed TXNIP promoted the migration and adhesion of THP-1 cells and expressions of NLRP3, IL-18 and IL-1β. Oppositely, knock-down TXNIP inhibited the migration and adhesion of THP-1 and expressions of NLRP3, IL-18. In conclusion, increased TXNIP expression, related to cg19693031 demethylation orientates monocytes towards an inflammatory status through the NLRP3 inflammasome pathway involved in the development of CAD. 相似文献
207.
208.
209.
Yan Jia Huanhuan Jin Liyuan Gao Xiang Yang Feixia Wang Hai Ding Anping Chen Shanzhong Tan Feng Zhang Jiangjuan Shao Shijun Wang Shizhong Zheng 《Journal of cellular and molecular medicine》2020,24(9):5304-5316
A growing number of studies recognize that long non‐coding RNAs (lncRNAs) are essential to mediate multiple tumorigenic processes, including hepatic tumorigenesis. However, the pathological mechanism of lncRNA‐regulated liver cancer cell growth remains poorly understood. In this study, we identified a novel function lncRNA, named polo‐like kinase 4 associated lncRNA (lncRNA PLK4, GenBank Accession No. RP11‐50D9.3), whose expression was dramatically down‐regulated in hepatocellular carcinoma (HCC) tissues and cells. Interestingly, talazoparib, a novel and highly potent poly‐ADP‐ribose polymerase 1/2 (PARP1/2) inhibitor, could increase lncRNA PLK4 expression in HepG2 cells. Importantly, we showed that talazoparib‐induced lncRNA PLK4 could function as a tumour suppressor gene by Yes‐associated protein (YAP) inactivation and induction of cellular senescence to inhibit liver cancer cell viability and growth. In summary, our findings reveal the molecular mechanism of talazoparib‐induced anti‐tumor effect, and suggest a potential clinical use of talazoparib‐targeted lncRNA PLK4/YAP‐dependent cellular senescence for the treatment of HCC. 相似文献
210.